Condensed Consolidated Statements of Equity (Deficit) - USD ($) $ in Thousands	Total	Cumulative Effect, Period of Adoption, Adjustment	Total Stockholders’ Equity	Total Stockholders’ Equity Cumulative Effect, Period of Adoption, Adjustment	Common Stock	Additional Paid-in Capital	Treasury Stock	Accumulated Other Comprehensive Loss	Noncontrolling Interests in Subsidiaries	Accumulated Deficit	Accumulated Deficit Cumulative Effect, Period of Adoption, Adjustment
Common stock, outstanding, beginning balance (in shares) at Dec. 30, 2018					141,178,000
Stockholders' equity, beginning of period at Dec. 30, 2018	$ (149,886)	$ 9,151	$ (208,696)	$ 9,151	$ 141	$ 2,463,370	$ (187,069)	$ (4,150)	$ 58,810	$ (2,480,988)	$ 9,151
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(104,565)		(89,724)						(14,841)	(89,724)
Other comprehensive income (loss)	99		99					99
Issuance of restricted stock to employees, net of cancellations (in shares)					1,848,000
Issuance of restricted stock to employees, net of cancellations	2		2		$ 2
Stock-based compensation expense	6,628		6,628			6,628
Purchases of treasury stock (in shares)					(633,000)
Purchases of treasury stock	(3,872)		(3,872)		$ (1)		(3,871)
Contributions from noncontrolling interests	20,987								20,987
Common stock, outstanding, ending balance (in shares) at Mar. 31, 2019					142,393,000
Stockholders' equity, end of period at Mar. 31, 2019	(221,456)		(286,412)		$ 142	2,469,998	(190,940)	(4,051)	64,956	(2,561,561)
Common stock, outstanding, beginning balance (in shares) at Dec. 30, 2018					141,178,000
Stockholders' equity, beginning of period at Dec. 30, 2018	(149,886)	9,151	(208,696)	9,151	$ 141	2,463,370	(187,069)	(4,150)	58,810	(2,480,988)	9,151
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Other comprehensive income (loss)	265
Common stock, outstanding, ending balance (in shares) at Jun. 30, 2019					142,515,000
Stockholders' equity, end of period at Jun. 30, 2019	(96,645)		(158,490)		$ 143	2,476,788	(191,434)	(3,885)	61,845	(2,440,102)
Common stock, outstanding, beginning balance (in shares) at Dec. 30, 2018					141,178,000
Stockholders' equity, beginning of period at Dec. 30, 2018	$ (149,886)	$ 9,151	(208,696)	$ 9,151	$ 141	2,463,370	(187,069)	(4,150)	58,810	(2,480,988)	$ 9,151
Common stock, outstanding, ending balance (in shares) at Dec. 29, 2019	168,121,000				168,121,000
Stockholders' equity, end of period at Dec. 29, 2019	$ 21,499		10,163		$ 168	2,661,819	(192,633)	(9,512)	11,336	(2,449,679)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accounting Standards Update [Extensible List]	us-gaap:AccountingStandardsUpdate201802Member
Common stock, outstanding, beginning balance (in shares) at Mar. 31, 2019					142,393,000
Stockholders' equity, beginning of period at Mar. 31, 2019	$ (221,456)		(286,412)		$ 142	2,469,998	(190,940)	(4,051)	64,956	(2,561,561)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	110,074		121,459						(11,385)	121,459
Other comprehensive income (loss)	166		166					166
Issuance of restricted stock to employees, net of cancellations (in shares)					173,000
Issuance of restricted stock to employees, net of cancellations	1		1		$ 1
Stock-based compensation expense	6,790		6,790			6,790
Purchases of treasury stock (in shares)					(51,000)
Purchases of treasury stock	(494)		(494)				(494)
Contributions from noncontrolling interests	8,590								8,590
Distributions from noncontrolling interests	(316)								(316)
Common stock, outstanding, ending balance (in shares) at Jun. 30, 2019					142,515,000
Stockholders' equity, end of period at Jun. 30, 2019	$ (96,645)		(158,490)		$ 143	2,476,788	(191,434)	(3,885)	61,845	(2,440,102)
Common stock, outstanding, beginning balance (in shares) at Dec. 29, 2019	168,121,000				168,121,000
Stockholders' equity, beginning of period at Dec. 29, 2019	$ 21,499		10,163		$ 168	2,661,819	(192,633)	(9,512)	11,336	(2,449,679)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(2,138)		(1,431)						(707)	(1,431)
Other comprehensive income (loss)	723		723					723
Issuance of restricted stock to employees, net of cancellations (in shares)					2,452,000
Issuance of restricted stock to employees, net of cancellations	3		3		$ 3
Stock-based compensation expense	6,885		6,885			6,885
Purchases of treasury stock (in shares)					(818,000)
Purchases of treasury stock	(6,911)		(6,911)		$ (1)		(6,910)
Common stock, outstanding, ending balance (in shares) at Mar. 29, 2020					169,755,000
Stockholders' equity, end of period at Mar. 29, 2020	$ 20,061		9,432		$ 170	2,668,704	(199,543)	(8,789)	10,629	(2,451,110)
Common stock, outstanding, beginning balance (in shares) at Dec. 29, 2019	168,121,000				168,121,000
Stockholders' equity, beginning of period at Dec. 29, 2019	$ 21,499		10,163		$ 168	2,661,819	(192,633)	(9,512)	11,336	(2,449,679)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Other comprehensive income (loss)	$ (853)
Common stock, outstanding, ending balance (in shares) at Jun. 28, 2020	170,059,000				170,059,000
Stockholders' equity, end of period at Jun. 28, 2020	$ 41,305		31,656		$ 170	2,674,379	(200,796)	(10,365)	9,649	(2,431,732)
Common stock, outstanding, beginning balance (in shares) at Mar. 29, 2020					169,755,000
Stockholders' equity, beginning of period at Mar. 29, 2020	20,061		9,432		$ 170	2,668,704	(199,543)	(8,789)	10,629	(2,451,110)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	18,398		19,378						(980)	19,378
Other comprehensive income (loss)	(1,576)		(1,576)					(1,576)
Issuance of restricted stock to employees, net of cancellations (in shares)					533,000
Issuance of restricted stock to employees, net of cancellations	0
Stock-based compensation expense	5,675		5,675			5,675
Purchases of treasury stock (in shares)					(229,000)
Purchases of treasury stock	$ (1,253)		(1,253)				(1,253)
Common stock, outstanding, ending balance (in shares) at Jun. 28, 2020	170,059,000				170,059,000
Stockholders' equity, end of period at Jun. 28, 2020	$ 41,305		$ 31,656		$ 170	$ 2,674,379	$ (200,796)	$ (10,365)	$ 9,649	$ (2,431,732)